BD Announces First Quarter Results and Plans to Separate Biosciences and Diagnostic Solutions

Details

The company also announced a board-authorized plan to separate its Biosciences and Diagnostic Solutions business, with more details expected by the end of fiscal 2025 and a targeted completion in fiscal 2026. BD completed $750 million in share repurchases to date in FY25 and raised its fiscal 2025 adjusted diluted EPS guidance to a range of $14.30 to $14.60.

Items reported

Exhibits (2)

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a prominent American multinational corporation engaged in the development and manufacture of a diverse range of medical devices, instrument systems, and reagents. A key player in the healthcare industry, BD focuses on improving medical discovery, diagnostics, and the delivery of care. BD's products are instrumental in supporting healthcare professionals worldwide in enhancing patient safety and reducing the risks associated with healthcare workers. The company operates across three main segments: BD Medical, BD Life Sciences, and BD Interventional, impacting various sectors such as pharmaceuticals, hospital healthcare systems, and clinical laboratories. With a strong commitment to innovation and quality, Becton, Dickinson and Company contributes significantly to advancements in patient care, operating efficiency in medical settings, and is noted for its commitment to addressing healthcare challenges on a global scale. Headquartered in Franklin Lakes, New Jersey, BD maintains a robust presence across numerous countries, underpinning its influential role in the evolution and improvement of global healthcare infrastructure.